WO2004076462A1 - Preparation of k-252a - Google Patents
Preparation of k-252a Download PDFInfo
- Publication number
- WO2004076462A1 WO2004076462A1 PCT/US2004/005808 US2004005808W WO2004076462A1 WO 2004076462 A1 WO2004076462 A1 WO 2004076462A1 US 2004005808 W US2004005808 W US 2004005808W WO 2004076462 A1 WO2004076462 A1 WO 2004076462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- product
- base
- hydroxide
- aqueous
- solvent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention provides a process for the preparation of K-252a and intermediates useful in the process.
- K-252a (methyl ( 15S, 16R, 1SR)-16-hydroxy- 15-methyl-3-oxo-28-oxa-4, 14,19- triazaoctacyclo[12.11.2.1 15 ' 18 .0 2 ' 6 .0 7 ' 27 .0 8>13 .0 19 ' 26 .0 20 ' 25 ]octacosa-l,6,8,10,12,20,22,24,26- nonaene-16-carboxylate) is a physiologically active substance produced by microorganisms which has demonstrated various pharmacological properties such as the ability to inhibit protein kinase C activity.
- Previously disclosed methods of isolating K-252a from microorganisms have proven to be inefficient when carried out on large amounts of material and have also been shown to generate the final product in low purity.
- crude K-252a can be hydrolyzed to provide K-252b (which is more easily purified) and subsequently alkylated to provide K-252a of high purity.
- This method has also shown to be impractical for the production of large amounts of material, however, due to the required column chromatography and the use of dimethylsulfate as an alkylating agent, which is highly toxic.
- the present invention discloses a preparation of K-252a which eliminates both the need for column chromatography and the use of dimethylsulfate.
- the present invention provides a process for preparing the compound of formula (II)
- an aqueous hydroxide base preferably an aqueous hydroxide base containing up to 25% organic solvent, more preferably an aqueous hydroxide base containing 20% acetone; most preferably aqueous sodium hydroxide or aqueous ammonium hydroxide containing 20% acetone;
- step (b) crystallizing the product of step (a);
- step (c) isolating the product of step (b).
- the present invention provides a process for preparing the compound of formula (II), the process comprising:
- step (c) optionally partially concentrating the product of step (b);
- step (d) isolating the product of step (b) or step (c) by filtration.
- step (c) isolating the product of step (b) or step (c) by filtration.
- the present invention provides a process for preparing the compound of formula (III)
- step (b) optionally treating the solution of step (a) with a base, preferably sodium bicarbonate, sodium carbonate, or potassium carbonate, most preferably sodium bicarbonate;
- a base preferably sodium bicarbonate, sodium carbonate, or potassium carbonate, most preferably sodium bicarbonate;
- step (c) treating the solution of step (a) or step (b) with methyl p-toluenesulfonate;
- the present invention provides a process for preparing the compound of formula (III)
- an aqueous hydroxide base preferably an aqueous hydroxide base containing up to 25% organic solvent, more preferably an aqueous hydroxide base containing 20% acetone; most preferably aqueous sodium hydroxide or aqueous ammonium hydroxide containing 20% 75 acetone;
- step (b) crystallizing the product of step (a);
- step (c) isolating the product of step (b);
- step (d) dissolving the product of step (c) in a solvent, preferably N,N-dimethylacetamide or N,N-dimethylformamide, most preferably N,N-dimethylacetamide;
- step (e) optionally treating the solution of step (d) with a base, preferably sodium carbonate, sodium bicarbonate, or potassium carbonate, most preferably sodium bicarbonate; and
- step (f) reacting the product of step (d) or step (e) with a methylating agent, preferably methyl p-toluenesulfonate.
- the present invention is directed to the preparation of K-252a (methyl ( 15S, 16R, 18R)- 16-hydroxy- 15-methyl-3-oxo-28-oxa-4, 14,19- triazaoctacyclo[12.11.2.1 15 ' 18 .0 2,6 .0 7 ' 27 .0 8 ' 13 .0 19 ' 26 .0 20 ' 25 ]octacosa-l,6,8,10,12,20,22,24,26- 90 nonaene-16-carboxylate) and to intermediates which are useful in this process.
- the following terms have the meanings specified:
- aqueous refers to a solution that contains up to 30% organic solvent wherein the remaining solution is water. Preferred aqueous solutions contain up to 25% organic solvent, and more preferred aqueous solutions contain up to 20% organic 95 solvent. Most preferred aqueous solutions contain 20% acetone.
- bases refers to a reagent capable of accepting protons during the course of a reaction.
- bases include carbonate salts such as potassium carbonate, potassium bicarbonate, sodium carbonate, sodium bicarbonate, and cesium carbonate; halides such as cesium fluoride; phosphates such as potassium phosphate, 100 potassium dihydrogen phosphate, and potassium hydrogen phosphate; hydroxides such as lithium hydroxide, sodium hydroxide, ammonium hydroxide, and potassium hydroxide; disilylamides such as lithium hexamethyldisilazide, potassium hexamethyldisilazide, and sodium hexamethyldisilazide; trialkylamines such as triethylamine, diisopropylamine, and diisopropylethylamine; heterocyclic amines such as imidazole, pyridine, pyridazine, 105 pyrimidine, and pyrazine; bicyclic amines such as imidazole
- the base chosen for a particular conversion depends on the nature of the starting materials, the solvent or solvents in which the reaction is conducted, and the temperature at which the reaction is conducted. 110
- hydrooxide base refers to lithium hydroxide, sodium hydroxide, potassium hydroxide, or ammonium hydroxide.
- solvent refers to an organic substance that is a liquid at between about 20 and about 35 °C and does not interact with starting materials, reagents, intermediates, or products in a manner which adversely affects the yield of the desired 115 product.
- Scheme 1 shows the synthesis of the compound of formula (III) (K-252a).
- the 125 compound of formula (I) (K-252b; prepared according to a modification of the procedures described in /. Antibiotics 1986, 39, 1059-1065 and Biosci. Biotechnol. Biochem. 1998, 62, 1627-1629) can be treated with an aqueous hydroxide base to provide the compound of formula (II).
- the aqueous hydroxide is sodium hydroxide or ammonium hydroxide. Examples of solvents used in this reaction include water, acetone, and mixtures 130 thereof.
- reaction is typically conducted at temperatures between about 20 °C and about 55 °C (depending on the solvent system used) and then cooled to a temperature of between about -5 °C and about 5 °C to induce crystallization.
- the resulting crystals are then isolated by filtration to provide the compound of formula (II).
- Reaction times are typically about 10 to about 24 hours.
- the compound of formula (I) is treated with 135 aqueous sodium hydroxide, stirred for one hour at room temperature, treated with acetone, cooled to about 0 °C for about 19 hours, partially concentrated, and filtered to provide the compound of formula (II).
- the compound of formula (II) can be converted to the compound of formula (III) (K- 252a) by treatment with a methylating agent, preferably methyl p-toluenesulfonate, 140 optionally in the presence of a base (to deprotonate any undesired compound of formula (I) remaining in the reaction).
- a methylating agent preferably methyl p-toluenesulfonate
- a base to deprotonate any undesired compound of formula (I) remaining in the reaction.
- Representative bases used in this reaction include sodium bicarbonate, sodium carbonate, and potassium carbonate.
- sodium acetate is added to decompose any remaining reagent.
- solvents used in this reaction include N,N-dimethylacetamide and N,N-dimethylformamide.
- reaction is typically conducted at about 35 °C to about 45 °C and then cooled to a temperature of between about 5 °C and about 30 °C. Water is added to precipitate the product which is then isolated by filtration to provide the compound of formula (III). Reaction times are typically about 6 to about 12 hours.
- K-252b sodium salt K-252b (prepared according to the procedures described in J. Antibiotics 1986, 39, 1059-1065 and Biosci. Biotechnol. Biochem. 1998, 62, 1627- 1629; 300 L) was concentrated 4-fold using reverse osmosis and then adjusted to pH 3.0 with HC1. The resulting precipitate
- 165 was isolated by filtration.
- a sample of the filtered precipitate (506.6g; 47.6 grams of activity) was crystallized as follows: The sample was treated with 3.5 L of 0.25M NaOH to obtain a concentration of approximately 1 l-12g of activity per liter. The mixture was stirred for about an hour at room temperature to form a suspension. The suspension was treated with 700 mL of acetone and the resulting solution was cooled to 0 °C over 6 hours during
- Vacuum was applied with slow stirring to remove the acetone. After acetone removal the solids were filtered and dried over the weekend to produce 25.37g of the desired product.
- K-252b sodium salt K-252b (prepared according to the procedures described in J. Antibiotics 1986, 39, 1059-1065 and Biosci. Biotechnol. Biochem. 1998, 62, 1627-1629;300 L) was concentrated 4-fold using reverse osmosis and then adjusted to pH 3.0 with HC1. The resulting precipitate
- 190 was isolated by filtration.
- a sample of the filtered precipitate (150g; 12.68 g of activity) was crystallized as follows: The sample was added to a reactor containing 1500 mL of 0.25M NaOH. The mixture was heated to about 53 °C until a solution was obtained. The mixture was cooled to 0 °C over 7 hours and held for 13 hours at 0 °C. The mixture was filtered and the filter cake was dried to provide 11.3g (-90% yield at 97.8% purity by peak area) of the
- Example 4 Preparation of K-252a from K-252b sodium salt
- a condenser a J-kem probe, and an addition 200 funnel was added Example 1 (5g; 9.78 mmol), sodium bicarbonate (0.55g; 6.54 mmol), and N,N-dimethylacetamide (23.3g).
- the reaction was heated to 40 °C S treated with methyl-p- toluenesulfonate (2.36g, 12.67 mmol), and stirred at 40 °C for about 3 to about 4 hours.
- the reaction was treated with sodium acetate (lg), stirred for 4 hours, cooled to room temperature, and treated slowly with water (85 mL).
- the resulting precipitate was filtered 205 and the filter cake was washed with water (60 mL) and air dried to provide 4.5g of the desired product.
- Example 5 Preparation of K-252a from K-252b ammonium salt 210
- the desired product can be prepared by substituting Example 2 for Example 1 in
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05009152A MXPA05009152A (en) | 2003-02-27 | 2004-02-26 | Preparation of k-252a. |
CA002515795A CA2515795A1 (en) | 2003-02-27 | 2004-02-26 | Preparation of k-252a |
EP04715117A EP1599486A1 (en) | 2003-02-27 | 2004-02-26 | Preparation of k-252a |
JP2006503892A JP2006519237A (en) | 2003-02-27 | 2004-02-26 | Preparation of K-252a |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/375,413 | 2003-02-27 | ||
US10/375,413 US6723844B1 (en) | 2003-02-27 | 2003-02-27 | Preparation of K-252a |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004076462A1 true WO2004076462A1 (en) | 2004-09-10 |
Family
ID=32069581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/005808 WO2004076462A1 (en) | 2003-02-27 | 2004-02-26 | Preparation of k-252a |
Country Status (7)
Country | Link |
---|---|
US (1) | US6723844B1 (en) |
EP (1) | EP1599486A1 (en) |
JP (1) | JP2006519237A (en) |
CA (1) | CA2515795A1 (en) |
MX (1) | MXPA05009152A (en) |
PL (1) | PL378080A1 (en) |
WO (1) | WO2004076462A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007013071A (en) * | 2005-04-20 | 2008-01-14 | Abbott Lab | Fermentation broth extraction of k-252a. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451786B1 (en) * | 1997-12-31 | 2002-09-17 | Cephalon, Inc. | 3′-epimeric k-252a derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61176531A (en) * | 1985-01-31 | 1986-08-08 | Kyowa Hakko Kogyo Co Ltd | Novel substance kt5556 and preparation thereof |
JPH07113027B2 (en) | 1987-12-24 | 1995-12-06 | 協和醗酵工業株式会社 | K-252 derivative |
CA2228471C (en) | 1996-04-09 | 2005-05-24 | Kyowa Hakko Kogyo Co., Ltd. | A process for purification of k-252a |
EP0987273A4 (en) * | 1997-06-03 | 2001-11-07 | Ajinomoto Kk | Process for preparing antifungal v-28-3m |
-
2003
- 2003-02-27 US US10/375,413 patent/US6723844B1/en not_active Expired - Lifetime
-
2004
- 2004-02-26 WO PCT/US2004/005808 patent/WO2004076462A1/en active Application Filing
- 2004-02-26 PL PL378080A patent/PL378080A1/en not_active Application Discontinuation
- 2004-02-26 MX MXPA05009152A patent/MXPA05009152A/en active IP Right Grant
- 2004-02-26 EP EP04715117A patent/EP1599486A1/en not_active Withdrawn
- 2004-02-26 JP JP2006503892A patent/JP2006519237A/en active Pending
- 2004-02-26 CA CA002515795A patent/CA2515795A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451786B1 (en) * | 1997-12-31 | 2002-09-17 | Cephalon, Inc. | 3′-epimeric k-252a derivatives |
Also Published As
Publication number | Publication date |
---|---|
US6723844B1 (en) | 2004-04-20 |
JP2006519237A (en) | 2006-08-24 |
MXPA05009152A (en) | 2005-10-20 |
CA2515795A1 (en) | 2004-09-10 |
EP1599486A1 (en) | 2005-11-30 |
PL378080A1 (en) | 2006-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3421354B2 (en) | Crystalline cefdiniramine salt | |
WO1997024358A1 (en) | Process for preparation of cefdinir | |
WO2006070349A2 (en) | Novel process for preparing pramipexole and its optical isomeric mixture by reduction with sodium triacetoxyborohydride | |
CZ267594A3 (en) | Process for preparing clavulanic acid, use and salts thereof | |
CN110590635A (en) | Preparation method of levetiracetam and intermediate thereof | |
RU2090566C1 (en) | Method of synthesis 9-substituted guanine derivatives | |
US6723844B1 (en) | Preparation of K-252a | |
SU558644A3 (en) | The method of obtaining imidazoles or their salts | |
BR112020001396A2 (en) | intermediates useful in the synthesis of aminopyrimidine derivatives, process for preparing them and process for preparing aminopyrimidine derivatives using the same | |
US6140527A (en) | Process for producing butyric ester derivatives | |
CN109836424B (en) | Method for preparing caffeine by methylation of environment-friendly theophylline sodium salt | |
US4847266A (en) | Method for preparing 6-β-halopenicillanic acids | |
CN111808040B (en) | Synthesis method of multi-configuration 2-oxo-oxazolidine-4-carboxylic acid compounds | |
EP1219593A1 (en) | Process for producing optically active aminoalcohol | |
US4267324A (en) | Process for preparing 4-aminopyrazolo-(3,4-d)pyrimidine | |
RU2227141C2 (en) | Method for preparing benzylamine | |
WO2008035189A1 (en) | A method for the purification of lansoprazole | |
JPH05222041A (en) | Method for purifying adenine derivative | |
JPH07300480A (en) | Improved process for producing 2-amino-6-chloropurine and 2-acylamino-6-chloro-purine | |
KR790001070B1 (en) | Process for preparing cephalosporin | |
JPH0324077A (en) | Production of imidazole derivative | |
JPH10195075A (en) | Production of z-valacyclovir | |
DE102005007110A1 (en) | Metallic salt of N4-acylcytidine derivatives and process for the preparation of N4-acylcytidine derivatives using it | |
JP2000001474A (en) | Production of n-benzyl-3-hydroxyazetidine | |
JPH0567623B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2515795 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 378080 Country of ref document: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/009152 Country of ref document: MX Ref document number: 2006503892 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004715117 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004715117 Country of ref document: EP |